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General introduction and thesis outlineDeprescribing in older people
CHAPTER 2
CHANGES IN PRESCRIBING SYMPTOMATIC 
AND PREVENTIVE MEDICATIONS IN THE 
LAST YEAR OF LIFE IN OLDER NURSING 
HOME RESIDENTS
Helene G van der Meer, Katja Taxis, Lisa G Pont
Frontiers in Pharmacology. 2018;8:990.
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Preventive medications at the end of life in older nursing home residents
ABSTRACT
Background At the end of life goals of care change from disease 
prevention to symptom control, however little is known about 
the patterns of medication prescribing at this stage.
Objectives To explore changes in prescribing of symptomatic 
and preventive medication in the last year of life in older nursing 
home residents.
Methods A retrospective cohort study was conducted using phar-
macy medication supply data of 553 residents from 16 nursing 
home facilities around Sydney, Australia. Residents received 24-h 
nursing care, were aged ≥ 65 years, died between June 2008 and 
June 2010 and were using at least one medication 1 year before 
death. Medications were classified as symptomatic, preventive or 
other. A linear mixed model was used to compare changes in pre-
scribing in the last year of life.
Results 68.1% of residents were female, mean age was 88.0 (SD: 
7.5) years and residents used a mean of 9.1 (SD: 4.1) medications 
1 year before death. The mean number of symptomatic medica-
tions per resident increased from 4.6 medications 1 year before 
death to 5.1  medications at death (95% CI 4.4–4.7 to 5.9–5.2, 
p  =  0.000), while preventive medication decreased from 2.0 to 
1.4 medications (95% CI 1.9–2.1 to 1.3–1.5, p = 0.000). Symptomatic 
medications were used longer in the last year of life, compared 
to preventive medications (336.3 days (95% CI 331.8–340.8) versus 
310.9 days (95% CI 305.2–316.7), p = 0.000).
Conclusions Use of medications for symptom relief increased 
throughout the last year of life, while medications for prevention 
of long-term complications decreased. But changes were slight 
and clinical relevance can be questioned.
INTRODUCTION
At all stages across the life span, the decision to prescribe a medi-
cation should be based on weighing potential benefits and harms 
of the medication considering the individual’s treatment goals. 
Goals range from decreasing mortality and morbidity, prevention 
of future conditions or complications, or minimisation of symp-
toms. Toward the end of life, in addition to considerations around 
potential medication related benefits and harms, treatment choice 
should also take life expectancy into consideration. As life ex-
pectancy decreases, the goals of care may change from decreasing 
mortality and morbidity, to symptom control. [1] Long-term res-
idential aged care or nursing home residents are among the frail-
est of all older populations. They are generally medically complex, 
using a high number of medications, and this complexity together 
with age-related pharmacokinetic- and dynamic puts them at high 
risk of adverse outcomes related to medication. [2–4]
Of all aged care residents, 91% die in the nursing home after an 
average stay of 168 weeks for women and 110 weeks for men, indi-
cating that the majority of residents have limited life expectancy 
following nursing home admission. [3] Adjusting prescribing 
according to a decreasing life expectancy involves deprescribing, 
defined as the process of withdrawing inappropriate medications. 
[5, 6] Hence in this population a decrease in preventive and an 
increase in the use of medications for symptom control and palli-
ation could be expected. [7]
To date few studies exploring changes in the use of symptom-
atic and preventive medications have been conducted in older 
nursing home populations at the end of life. A recent system-
atic review found that use of preventive medications in patients 
with limited life expectancy was common. [8] Only few studies 
focused on deprescribing and there was no consensus on how 
to optimise medication use at the end of life. Of the 15 studies 
included, three were performed in a nursing home setting. [8] 
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These studies included only a small study population [9] or had a 
cross-sectional study design. [10, 11] In order to consider optimi-
sation of medication use at the end of life we need to understand 
the current patterns of use as life expectancy decreases. Therefore, 
the aim of this study was to explore changes in prescribing of 
symptomatic and preventive medications in the last year of life 
among older nursing home residents.
METHODS
Study design and setting
A retrospective cohort study of 3876 nursing home residents liv-
ing in 26 residential aged care (RAC) facilities in New South Wales, 
Australia between 1st June 2008 and 10th June 2010. The RAC fa-
cilities varied from low care to high care. High care facilities pro-
vided 24 h nursing care including medication administration. All 
residents received medical care from the general practitioner of 
their choice and were eligible to receive annual medication re-
views by a pharmacist. Each facility has a contracted pharmacy for 
medication supply.
Study population
Recruitment was done at the facility level. All residents aged 65 
years or older who died in one of the 26 RAC facilities between 
2nd of June 2008 and 10th of June 2010 were included in the co-
hort. To allow medication changes in the year prior to death to 
be explored, only those residents who were taking at least one 
medication 1 year prior to death were included in the cohort. 
Residents who were discharged prior to death were excluded 
from the study, as medication use could not be ascertained once 
they left the facility.
Data source
Weekly pharmacy medication supply data, including all prescrip-
tion, non-prescription and complementary medications, were 
used for the study. The dataset included generic name, dose, date 
of commencement, date of cessation and if the use was regular 
or ‘as needed’. The dataset also included limited demographic data 
for each resident including age, sex, date of admission, date and 
reason for discharge and facility.
Medication classification
Medications were coded using the World Health Organization 
Anatomical Therapeutic Chemical (ATC) code. [12] Medications 
were classified into three categories: symptomatic, preventive and 
other. All medications recommended for symptom control in the 
Australian national palliative care guidelines were considered as 
symptomatic medications. [13, 14] Medications defined in the lit-
erature for primary or secondary prevention of all-cause mortality 
were defined as preventive medications. [15] Preventive medica-
tions included antihypertensive medications, [16] antithrombotic 
agents, [17] osteoporosis medication [18] and lipid modifying 
agents. [19] Medications that were not considered as either pre-
ventive or symptomatic were classified as other. Antibiotics, top-
ical preparations, ophthalmological and otological medications 
were excluded due to the episodic nature of the use of these med-
ications. Vaccines were also excluded as they were administered 
by the general practitioner and not supplied by the pharmacy. A 
list of included medications can be found in the Appendix.
Outcomes
Three main outcome measures were determined. Firstly, we com-
pared the mean number of symptomatic, preventive and other 
medications per resident at 1 year, 6 months, 1 month and 1 week 
(8 days) before death and on the day of death. Secondly, we com-
pared the type of symptomatic, preventive and other medication 
used 1 year before death versus on the day of death. For this anal-
ysis we included all medications, grouped by ATC level 2, which 
were used by at least 10% of the population either 365 days before 
death or on the day of death. Thirdly, we compared the duration 
of use of symptomatic, preventive and other medications in the 
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last year of life. We included all medications used 365 days before 
death, and calculated the days of treatment during the last year 
of life.
All medications used 7 or fewer days before death were consid-
ered to be taken on the day of death. This was done for two rea-
sons. Firstly, medication was supplied per week, therefore the 
last medication might have been supplied up to 7 days before 
death. Secondly, we assumed some inaccuracies in recording the 
date of death due to a delay in nursing home staff notifying phar-
macy staff.
Statistical analysis
Medication changes were analysed with a linear mixed model to account 
for clustering of medications within one resident. Our data did not allow 
clustering for general practitioners. Therefore we performed clustering on 
the level of facility, to account for possible intra-facility culture of medi-
cation prescribing. We included a random intercept and a random slope at 
the level of resident and facility in the analysis. Analyses were adjusted for 
age, gender, duration of admission and number of medications at 365 days 
before death, if the individual p-value in the univariate analysis was 0.25 or 
less. [20] The number of medication and days of treatment were reported as 
estimated marginal means with their 95% confidence intervals. The second 
outcome was analysed using a McNemar test. We report on proportions and 
absolute numbers of residents. All analyses were conducted in IBM SPSS 24 
on a significance level of 0.05.
Ethical approval 
This study was approved by the Sydney South West Area Health 
Service Human Research Ethics Committee, the Concord 




The cohort comprised of 553 residents out of the 3876 residents 
contained in the dataset (Figure 1).
Residents were between 65 and 105 years of age and lived in 16 dif-
ferent facilities. The average facilities size was 35 (SD: 21) residents 
per facility (range: 5–71) (Table 1).
Number of symptomatic, preventive and other medications in 
the last year of life
The total number of medications per resident decreased from 
9.1 (95% CI 8.9–9.3) medications 1 year prior to death to 8.5 
(95% CI 8.5–8.9) medications at death (p = 0.002). Symptomatic 



























Residents in database 
n = 3876 
Excluded (n = 2904): 
- Age < 65 years (n = 241) or unknown date of birth (n = 
138) 
- Not high care facility (n = 1549), facility with data issues 
(n = 104), facility with unknown care level (n = 50) 




n = 972 
 
Excluded (n = 419): 
- Stayed < 365 days in nursing home before death (n = 413)  
- No recorded symptomatic, preventive or other medication 
history at 365 days before death (n = 6) 
Study cohort 
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medication use increased from 4.6 to 5.1 (95% CI 4.4–4.7 to 
5.9–5.2, p = 0.000) medications, while preventive and other med-
ication decreased, respectively 2.0 to 1.4 (95% CI 1.9–2.1 to 1.3–1.5, 
p = 0.000) and 2.6–2.2 (95% CI 2.4–2.7 to 2.1–2.4, p = 0.000), to-
ward death (Figure 2).
Type of symptomatic, preventive and other medication used in 
the last year of life
Analgesics were the most frequently used type of medication over 
the last year of life. Analgesic use did not change significantly 
during the last year of life and was comparable at 1 year before 
death and at death, (85.0% to 86.1% of patients, p = 0.610). A shift 
in the type of analgesics used was seen, shifting from paracetamol 
to opioids, respectively 83.4% to 77.9% (p = 0.005) and 18.1% to 
44.5% (p = 0.000). Other significant changes in use of symptom-
atic medications toward death were only seen for diuretics (30.2% 
to 26.0%, p = 0.009) and medications for gastrointestinal disorders 
(17.2% to 22.8%, p = 0.000). In contrast, all preventive medications 
decreased significantly from 1 year before death until death. The 
highest decrease was found in mineral supplements (including cal-
cium), agents acting on the renin-angiotensin-aldosterone-system 
(RAAS) and lipid modifying agents, those respectively decreased by 
9.2% (p = 0.000), 8.9% (p = 0.000) and 8.1% (p = 0.000) (Table 2). 
However, at death about one third of all residents was using at least 
one antihypertensive medication (35.8%), one medication for oste-
oporosis (32.9%) or an antithrombotic medication (33.1%).
Duration of use of symptomatic, preventive and other 
medications in the last year of life
Symptomatic, preventive and other medications were used respec-
tively for 336.3 [95% CI 331.8–340.8], 310.9 [95% CI 305.2–316.7] 
and 320.5 [95% CI 315.2–325.8] days in the last year of life. 
Preventive and other medications were ceased earlier than symp-
tomatic medication, respectively 25.4 days earlier [EMM, 95% CI 




Throughout the last year of life we saw little change in overall 
medication use. Medications commonly used for symptom con-
trol slightly increased, while a small decrease in medication for 
disease-prevention was seen. However at death, preventive med-
ication such as antithrombotic agents, antihypertensive medica-
tions and osteoporosis medications were still prescribed to one 
third of all residents.
Table 1: Resident characteristics
Characteristic Residents (n = 553)
Age, mean years (SD) 88.0 (7.5)
Gender, % female (number) 68.1 (374)*
Length of stay in RAC facility, mean weeks (SD) 187.9 (104.4)
Number of medications 365 days before death, mean (SD) 9.1 (4.5)
Number of medications at death, mean (SD) 8.7 (5.1)
*n =549, gender was missing for 4 residents
Figure 2: Number of symptomatic, preventive, and other medication in the 
last year of life. Estimated marginal means (EMMs), adjusted for number 
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Changes in medication use at the end of life
The characteristics of our cohort of residents are similar to other 
studies in this setting, so we believe our sample is representative 
for the nursing home population in Australia. The residents’ av-
erage duration of stay in the RAC facility was slightly higher than 
the national average, which might be a consequence of selecting 
patients who stayed at least 1 year in the RAC. [3]
We found an increase in symptomatic medication toward death, 
which was also seen in a small study looking at the last 3 months 
of life [9] and another study focusing at the last week of life. [21] 
The increase was very subtle, however, and mostly caused by an 
increase in gastrointestinal medications. Overall use of analgesics, 
which are supposed to be the most prominent medication group 
in palliative care, [13] did not change. But the shift from parac-
etamol to opioid use indicates some awareness in the changing 

































































































































































































































































































































































































































































































































































































































































































Figure 3: Duration of use of symptomatic, preventive and other medica-
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Despite some deprescribing, the use of antithrombotics, antihy-
pertensives, and osteoporosis medications was very high at the 
end of life, similar to other studies. [10, 11, 21] An explanation for 
this high use could be the lack of consensus on what medications 
are considered solely preventive and therefore inappropriate at 
the end of life. [22] We included antithrombotics, lipid-modify-
ing agents, antihypertensives and osteoporosis medication, but 
other studies have also included iron, antibiotics, acid reducers 
and medications used in diabetes. [8] An exception to preventive 
medications, are lipid-modifying agents. These medications, es-
pecially statins, were unanimously classified as preventive med-
ication and have been explored the most. [8] This attention to 
statins might have led to growing awareness of its inappropri-
ateness at the end of life, resulting in early deprescribing by GPs. 
This could explain the lower use of statins compared to other pre-
ventive medication we found in our study.
Strengths and limitations
This study is unique in investigating changes in prescribing of 
symptomatic and preventive medication in the last year of life in 
a relatively large group of residents. We based the classification 
of medications on current guidelines. Some limitations need be 
taken into consideration when interpreting our results. Firstly, we 
were using medication supply data and therefore were not able to 
ascertain actual medication intake. However, the weekly medica-
tion supply ensured that the dataset remained relatively sensitive 
to change. Secondly, in line with other studies using dispensing 
data, we had no recorded indication for prescribed medication 
and therefore our medication classification was an approximation. 
We used the palliative care guidelines for classification of medica-
tion and rely on prescribing following the guidelines for correct 
classification. Thirdly, we were not able to cluster our data at the 
level of prescriber since each nursing home resident in Australia 
has his or her own prescriber. Fourthly, by investigating prescrib-
ing in the last year of life we had to exclude residents who stayed 
in the nursing home facility for a shorter time. Our results may 
not be generalisable to residents who died within a few months of 
nursing home admission.
CONCLUSION AND IMPLICATIONS FOR FURTHER RESEARCH
The awareness of deprescribing inappropriate medication at the 
end of life is growing throughout the literature. Recent articles 
have been published guiding the process of deprescribing [5, 23, 
24] and shared decision making at the end of life. [25] But there 
still remains a lack of high quality evidence guiding deprescribing 
at the end of life. [26] For example aspirin has a number needed 
to treat of 120 patients over 6 years to prevent one cardiovascular 
event and a number needed to harm of 73 for a non-trivial bleed-
ings, based on a study population with a mean age of 57 years. 
[27] The figures are likely to be different in an older population. 
Furthermore, contradictory recommendations and variation in 
interpretations of guidelines leads to clinical uncertainty. [28] An 
example is the most recent discussion on blood pressure control 
in older patients. [29] Exploring the use of preventive and symp-
tomatic medication at the end of life is a first step to improve the 
quality of medication use for these patients.
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Appendix: Classification of medications used by our cohort into symptom-
atic, preventive or other
ATC code Name Category
A01AD11 Various agents for local oral treatment Other
A02AB01 Aluminium Hydroxide Other
A02AD01 Ordinary salt combinations Other
A02AF02 Ordinary salt combinations and antiflatulents Other
A02BA03 Famotidine Other
A02BX13 Alginic acid Other
A03AA04 Mebeverine Other
A03AX Other drugs for functional gastrointestinal disorders Other
A05BA03 Silymarin Other
A06AA Softeners, emollients Other
A06AC03 Sterculia Other
A07C Electrolytes with carbohydrates Other
A07EC01 Sulfasalazine Other
A07EC02 Mesalazine Other
A09A Digestives, including enzymes Other
A10AB Fast-acting insulins Other
A10AC Intermediate-acting insulins Other









A11GB Ascorbic acid, combinations Other
A11JD Other vitamin products, combinations Other
A12BA Potassium Other
A12BA01 Potassium chloride Other
A12CA01 Sodium chloride Other
A12CB01 Zinc sulfate Other
A12CC Magnesium Other
A12CC05 Magnesium aspartate Other
B02BA01 Phytomenadione Other
B03A Iron preparations Other
ATC code Name Category
B03BA01 Cyanocobalamin Other
B03BB Folic acid Other





C01DA02 Glyceryl Trinitrate Other
C01DA08 Isosorbide Dinitrate Other







G04BX Sodium citrotartrate Other
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Chondroitin sulfate and Glucosamine Other














N04BA02 Levodopa and decarboxylase inhibitor Other

















































R03AK06 Fluticasone and Salmeterol Other




R03BB01 Ipratropium bromide Other
R03BB04 Tiotropium bromide Other
R03DA04 Theophylline Other
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V03AE01 Polystyrene Sulfonate Other
V03AG Sodium itamine phosphate Other
A11CC Vitamine D and itamin D analogues Preventive
A12A Calcium Preventive
B01 Antithrombotic agents Preventive
C02 Antihypertensives Preventive
C03 Diuretics (except for hydrochlorothiazide, frusemide, 
spironolactone)
Preventive
C07 Betablocking agents Preventive
C08 Calcium channel blockers (except for nifedipine and 
diltiazem)
Preventive
C09 Agents acting on the renin angiotensin system Preventive
C10A Lipid modifying agents (plain) Preventive
C10B Lipid modifying agents (combinations) Preventive
G03C Estrogen Preventive
G03F Progesteron Preventive
G03XC01 Raloxifene hydrochloride Preventive




M05BA Bisphosphonates (except for clodronic acid, pamid-
romic acid, ibedronic acid, zoledronic acid)
Preventive
M05BB Bisphosphonates combinations Preventive
M05BX03 Strontium ranelate Preventive










A03AB02 Glycooyrronium bromide Symptomatic
A03AB05 Propantheline Symptomatic












A06AA01 Liquid paraffin Symptomatic
A06AA02 Docusate Symptomatic
A06AB02 Bisacodyl Symptomatic
A06AB06 Senna glycosides Symptomatic
A06AB08 Sodium picosulphate Symptomatic
A06AB56 Senna glycosides combinations Symptomatic
A06AC01 Ispaghula (psylla seeds) Symptomatic
A06AC53 Stericula combinations Symptomatic
A06AD11 Lactulose Symptomatic
A06AD15 Macrogol Symptomatic
A06AD17 Sodium phosphate Symptomatic
A06AD18 Sorbitol Symptomatic






A10AE04 Long acting insulin Symptomatic
B02AA02 Tranexamic acid Symptomatic
B05B I.V. solutions Symptomatic
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H02AB10 Cortisone acetate Symptomatic
J02AC01 Fluconazole oral Symptomatic
J02AC02 Itraconazole oral Symptomatic










M05BA02 Clodronic acid Symptomatic
M05BA03 Pamidronic acid Symptomatic
M05BA06  Ibedronic acid Symptomatic
M05BA08 Zoledronic acid Symptomatic




N02AA01 Morphine hydrochloride Symptomatic










N03AG01 Sodium Valproate Symptomatic
N03AX12 Gabapentin Symptomatic
N03AX16 Pregabalin Symptomatic
N04AC01 Benzatropine Symptomatic
N05AA01 Chlorpromazine Symptomatic
N05AA02 Levomepromazine Symptomatic
N05AB04 Prochlorperazine Symptomatic
N05AD01 Haloperidol Symptomatic
N05AH03 Olanzapine Symptomatic
N05AX08 Risperidone Symptomatic
N05BA01 Diazepam Symptomatic
N05BA04 Oxazepam Symptomatic
N05BA06 Lorazepam Symptomatic
N05BA12 Alprazolam Symptomatic
N05CD02 Nitrazepam Symptomatic
N05CD07 Temazepam Symptomatic
N05CD08 Midazolam Symptomatic
N06AA09 Amitriptyline Symptomatic
N06AA10 Nortriptyline Symptomatic
N06AA12 Doxepin Symptomatic
N06AB05 Paroxetine Symptomatic
N06AX16 Venlafaxine Symptomatic
N06AX21 Duloxetine Symptomatic
N06BA02  Dexamfetamine Symptomatic
N06BA04 Methylphenidate Symptomatic
N07BC02 Methdadone Symptomatic
R06AD01 Alimemazine Symptomatic
R06AD02 Promethazine Symptomatic
R06AE03 Cyclizine Symptomatic
